Clearmind Medicine Completes Treatment And Follow-Up for 18 Participants In Ongoing Phase I/IIa Trial Of CMND-100 For Alcohol Use Disorder

Clearmind Medicine Inc. announced the successful completion of treatment and follow-up for 18 participants in its ongoing FDA-approved Phase I/IIa clinical trial evaluating CMND-100, the company’s proprietary non-hallucinogenic MEAI-based oral drug candidate for the treatment of Alcohol Use Disorder (AUD).

This milestone demonstrates continued positive progress and strong momentum in the multinational, multicenter study, which is designed to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100 in patients with moderate to severe AUD.

In addition, four more participants have been successfully treated at the Tel Aviv clinical center, further expanding enrollment and highlighting the operational strength of the Israeli sites within the trial.

Dr. Adi Zuloff-Shani, Chief Executive Officer of Clearmind Medicine, said the completion of treatment and follow-up for these participants, along with the rapid addition of new patients, reflects the favorable safety and tolerability profile of CMND-100. He added that this steady progress across multiple sites brings the company closer to delivering an innovative therapy for patients with Alcohol Use Disorder, addressing a significant unmet medical need.

The Phase I/IIa clinical trial is being conducted at leading institutions, including Yale University, Johns Hopkins University, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center, ensuring rigorous evaluation of CMND-100 across diverse patient populations and clinical settings.